Abstract
Because WT1 is expressed in leukemia cells, the development of cancer immunotherapy targeting WT1 has been an attractive translational research topic. However, concern of this therapy still remains, since WT1 is abundantly expressed in renal glomerular podocytes. In the present study, we clearly showed that WT1-specific cytotoxic T lymphocytes (CTLs) certainly exerted cytotoxicity against podocytes in vitro; however, they did not damage podocytes in vivo. This might be due to the anatomical localization of podocytes, being structurally separated from circulating CTLs in glomerular capillaries by an exceptionally thick basement membrane.
| Original language | English |
|---|---|
| Article number | 3 |
| Journal | Journal of Hematology and Oncology |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 06-01-2014 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Hematology
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver